Natco Pharma Ltd.’s net profit slipped 37% in the third quarter of financial year 2024-2025, thereby missing analysts’ estimates.
The pharma firm posted a consolidated net profit of Rs 133 crore in the quarter ended Dec. 31, 2024, as compared to Rs 212.70 crore in the same period last year, according to an exchange filing on Wednesday. This compares to the consensus estimate of Rs 247 crore of analysts tracked by Bloomberg.
The company’s revenue dipped to Rs 474.80 crore, representing a 37.4% fall as against Rs 758.60 crore for the year ago period. This compares to the consensus estimate of Rs 877 crore of analysts tracked by Bloomberg.
Its earnings before interest, tax, depreciation and amonatisation tumbled by 86% to Rs 38.79 crore for the October- December quarter from Rs 268.10 crore for the same quarter of the corresponding year.
Margin narrowed drastically to 8.2% for the quarter under review as contrast to 35.3% for the same period of the previous fiscal 2025.
